| |
With a 60+ year legacy of excellence in bioscience manufacturing, Puerto Rico is a hub for groundbreaking discoveries in the region & beyond. Local talent, tax benefits & the island's decades of expertise fuel companies like CytoImmune & OcyonBio. Learn more.
|
|
Today’s Big NewsJan 30, 2024 |
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.
|
|
| By Annalee Armstrong Catamaran Bio’s voyage is ending early as the cell therapy biotech winds down operations and tries to find a new partner for its allogeneic solid tumor therapies. |
|
|
|
By Angus Liu The price-negotiation component of the Inflation Reduction Act appears right up ICER’s alley. But the watchdog’s new president says there’s a condition that needs to be met for the organization to regularly contribute to the process. |
By Andrea Park “Imagine if Stephen Hawking could communicate faster than a speed typist or auctioneer. That is the goal," Neuralink founder Elon Musk wrote on X on Monday. |
By Annalee Armstrong Once again, 2seventy bio is splitting in two, but this time the shift is seismic. The cell therapy company is offloading pre-clinical and clinical cell therapy programs to Regeneron to form a new unit and laying off staff. |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way,providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.
|
|
By Kevin Dunleavy In its second quarter on the market, Pfizer’s Abrysvo generated worldwide sales of $515 million. Combined with its sales of $375 million in the previous period, the RSV vaccine appears to be gaining traction but is still lagging GSK's Arexvy. |
By Conor Hale 2023 saw Danaher spin out one slate of companies and acquire another, while COVID testing tailwinds turned into headwinds, according to CEO Rainer Blair. |
By Gabrielle Masson Pfizer is trimming its pipeline (and team), discarding three assets after R&D spending dropped 24% in the last quarter of 2023. |
By Angus Liu The FDA has approved a manufacturing process that allows Gilead's Kite to shorten Yescarta's manufacturing time from an average of 7 days to 5 days. |
By Andrea Park With an eye toward better matching its targeted therapeutics to the patients who will benefit most, Incyte has turned to Agilent Technologies to develop companion diagnostics for the drugs. |
By Nick Paul Taylor Vertex’s long-running attempt to crack the blockbuster pain market has finally delivered a pair of phase 3 wins. And yet, the positive news was tempered by the failure to hit key secondary endpoints designed to show the non-opioid medicine is more effective than an existing, widely-used painkiller. |
By Fraiser Kansteiner 2seventy Bio has traveled a difficult path ever since it spun out from bluebird bio to work on cancer cell therapies. Now, the company is splitting in two once again, passing its R&D programs to Regeneron and going all-in on its Bristol Myers Squibb-partnered CAR-T Abecma. |
By Andrea Park Only a few months after unveiling its new dual-array hand-held ultrasound device—with FDA clearance already in hand—Clarius Mobile Health is venturing further afield. |
By Max Bayer Is the hottest club in biotech a football stadium? Sunday's NFC Championship at Levi's Stadium in San Francisco drew biotech vets from around the country. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Kevin Dunleavy,Zoey Becker In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcastsDon’t miss an episode |
| | While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. |
|
|---|
|
|
|
This white paper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. Built on proven methods used across industries, the Stage-Gate approach mitigates risk while shortening cycle times throughout the project lifecycle. Download now.
|
|
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
